Frederic H Moll
CIK 1260157 · Executive Chairman · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SWAV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SEATTLE, WA 98112
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PRCT | Director | 866,474 | $19.76 | $17.12M | $7.72M | 9 | 2026-06-10 |
| SSII | Director | 10,775,485 | $2.40 | $25.86M | $2.00M | 1 | 2026-03-10 |
| Shockwave Medical, Inc. (SWAV) Delisted | Director | 33,960 | $334.75 | $11.37M | -$15.92M | 11 | 2024-05-31 |
| Intersect ENT, Inc. (XENT) Delisted | Director | 260,961 | $28.24 | $7.37M | -$947.9K | 23 | 2021-02-05 |
| Venus Concept Inc. (HAIR) Delisted | Director | 13,825 | — | — | $500.0K | 5 | 2019-11-07 |
| BIOLASE, INC (BIOL) Delisted | Director | 20 | $0.02 | $0 | $0 | 9 | 2017-07-03 |
| HANSEN MEDICAL INC (HNSN) Delisted | Executive Chairman | 279,008 | — | — | $1.91M | 14 | 2012-03-05 |
Recent Filings · Page 7 of 10
94 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-08-29 | BIOLASE, INC (BIOL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-08-07 | Intersect ENT, Inc. (XENT) Delisted | Exer (M) | +16,250 | $100.8K | EDGAR |
| 2014-07-29 | Intersect ENT, Inc. (XENT) Delisted | Conv (C) | +276,178 | $0 | EDGAR |
| 2013-12-17 | — | Disp (D) | −234,168 | -$7.03M | |
| 2013-06-11 | BIOLASE, INC (BIOL) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-06-05 | — | Grant (A) | — | $0 | |
| 2012-06-12 | — | Grant (A) | — | $0 | |
| 2012-05-11 | — | Buy (P) | +5,000 | $120.8K | |
| 2012-03-05 | HANSEN MEDICAL INC (HNSN) Delisted | Sell (S) | −34,800 | -$110.2K | EDGAR |
| 2011-12-16 | HANSEN MEDICAL INC (HNSN) Delisted | Sell (S) | −13,385 | -$33.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.